Dental Implant Industry – Page 3

Nobel Biocare CEO Replaced
March 11, 2018 admin Comment

Nobel Biocare`s CEO Heliane Canepa has been replaced. Domenico Scala has been named its new chief executive, replacing Heliane Canepa, as of Sept 1, 2007. Nobel Biocare Chairman, Rolf Soiron, explained the decision to replace Canepa by saying: `An international company of this size should not be so greatly identified with a single person as has been the case at Nobel Biocare`. Swiss Sunday paper, SonntagsZeitung, reported Heliane Canepa has come under fire over allegations that the Swedish-Swiss dental implant

US ban on Biora Products costs Straumann 10 million Swiss Francs
March 11, 2018 admin Comment

The continuing FDA ban on importation of Biora`s Emdogain and Bone Substitute has cost parent company Straumann 10 million Swiss francs (8.14 million US$). Straumann chief executive Gilbert Achermann described the loss as `painful`. He furthermore stated that `The US FDA will reinspect our facility in Malmo, but we are not in a position to say when this will happen, If all goes well`, Biora products `could be reintroduced in the US in the first quarter of this year,` Additionally,

Novartis acquires 10% stake in Thommen Medical
March 11, 2018 admin Comment

Novartis, the Swiss pharmaceutical giant has taken a 10% stake in Swiss dental implant manufacturer Thommen Medical. According to a press release, Novartis`s stake will rise to 20% later in the summer. Andreas Stutz, Thommen Medical CEO says: “Novartis is a strategic partner for us. This opens completely new possibilities in the area of research. The understanding of soft-tissue and bone biology becomes more and more important for the producers of dental implants. Furthermore, we see the interest of Novartis

Controversy over the high price of Dental Implants
March 11, 2018 admin Comment

Dr. Gerald Niznick of Implant Direct sent a letter to the Editor of IJOMI taking issue with its recent Editorial (JOMI 2006; 21:6) that claimed a direct correlation between innovation and high prices for dental implants. Dr. Niznick`s letter analyzes the published financial statements of Nobel Biocare and Straumann showing their cost of goods at 16% to 20% with marketing expenses in excess of 40% and research costs of only 3.5% – 5% of gross revenues. The editor saw fit

Merrill Lynch`s Implant Industry Report
March 11, 2018 admin Comment

A Merril Lynch analyst`s report on the dental implant industry has been released. Issues discussed include: the risk of increasing regulation of implant placement, image guided surgery`s growing importance, Nobel Biocare`s sales strategy and various implant company`s product launches. As always, a very interesting read.

1 23